Display Settings:

Format

Send to:

Choose Destination
    Jpn J Clin Oncol. 1999 Nov;29(11):562-70.

    Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group.

    Source

    Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.

    Abstract

    OBJECTIVE:

    The aims of this randomized, controlled study were to investigate the efficacy and safety of long-term monotherapy with the luteinizing hormone-releasing hormone agonist goserelin acetate compared with both short- and long-term combined androgen blockade.

    METHODS:

    Patients with advanced prostate cancer (n = 371) were randomized to treatment with goserelin acetate alone or a combination of goserelin acetate plus either long-term or short-term antiandrogen (chlormadinone acetate) or short-term estrogen (diethylstilbestrol diphosphate).

    RESULTS:

    There were no significant differences between the treatment groups with respect to objective progression, overall survival or disease-specific survival. Nevertheless, subgroup analysis suggested that patients with minimal disease or a good prognosis might benefit more from combined androgen blockade than other patients. Combined androgen blockade significantly reduced the incidence of disease flare compared with goserelin acetate treatment alone.

    CONCLUSIONS:

    Neither short- nor long-term combined androgen blockade had a survival advantage over goserelin acetate alone.

    PMID:
    10678560
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Click here to read

      Chemical compound information

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk